• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    2/14/23 10:10:07 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email
    SC 13G/A 1 p23-0589sc13ga.htm RELMADA THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  3)*
     

    Relmada Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    75955J402

    (CUSIP Number)
     

    December 31, 2022

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 75955J40213G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,067,824 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,067,824 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,067,824 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.9%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 75955J40213G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,067,824 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,067,824 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,067,824 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.9%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 75955J40213G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Relmada Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      75955J402

     

     

    CUSIP No. 75955J40213G/APage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _______________________________

     

    Item 4. OWNERSHIP.
         
        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 30,099,203 Shares outstanding as of November 7, 2022, as reported in the Company's Quarterly Report filed on Form 10-Q for the quarterly period ended September 30, 2022 with the Securities and Exchange Commission on November 10, 2022.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

     

    CUSIP No. 75955J40213G/APage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 75955J40213G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 14, 2023

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

     

    Get the next $RLMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    10/14/2022$81.00 → $8.00Buy → Neutral
    Goldman
    10/14/2022$90.00 → $10.00Buy → Hold
    Truist
    10/14/2022Buy → Neutral
    Guggenheim
    10/13/2022$64.00 → $7.00Outperform → Perform
    Oppenheimer
    12/20/2021$50.00 → $42.00Outperform
    SVB Leerink
    More analyst ratings

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advanci

      5/12/25 4:01:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the

      5/8/25 7:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

      90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release "GEM/DOCE" formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point

      4/28/25 1:38:43 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Relmada Therapeutics Inc.

      10-Q - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      5/12/25 4:06:07 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      5/12/25 4:05:54 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Relmada Therapeutics Inc.

      424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

      4/28/25 1:46:21 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:44 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:12 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:02:33 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:44 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:03:12 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

      4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

      5/20/25 6:02:33 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

      CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors. Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy

      1/12/23 8:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

      CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program.  Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise

      1/9/23 8:00:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

      Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla., July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. "My due diligence performed before joi

      7/21/22 8:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Relmada Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously

      12/5/24 8:17:30 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics upgraded by Jefferies with a new price target

      Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously

      9/17/24 7:49:37 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously

      6/5/24 7:16:28 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Financials

    Live finance-specific insights

    See more
    • Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webcast Today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advanci

      5/12/25 4:01:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the

      5/8/25 7:30:00 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial re

      3/27/25 4:05:00 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      11/14/24 9:41:31 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      3/6/24 4:15:42 PM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

      SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

      2/14/24 8:53:47 AM ET
      $RLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care